Trading in Novo Nordisk shares by board members, executives and
associated persons as reported to Novo Nordisk on 6 February 2009
In accordance with Section 28a of the Danish Securities Trading Act,
Novo Nordisk is required on a daily basis to publish trading in Novo
Nordisk shares by the company's board members, executives and their
associated persons as reported by those persons to Novo Nordisk.
Please find below a statement of such trading in shares issued by
Novo Nordisk.
+-------------------------------------------------------------------+
| Name | Anne Marie Kverneland |
|---------------------------------+---------------------------------|
| Reason for reporting | Member of the Board of |
| | Directors |
|---------------------------------+---------------------------------|
| Financial instrument and ID | Novo Nordisk B DK006010261 |
| code | |
|---------------------------------+---------------------------------|
| Type of transaction | Sale of shares |
|---------------------------------+---------------------------------|
| Date of transaction | 6 February 2009 |
|---------------------------------+---------------------------------|
| Place of transaction | NASDAQ OMX Copenhagen |
|---------------------------------+---------------------------------|
| Volume of transaction | 328 shares |
|---------------------------------+---------------------------------|
| Total value of transaction | DKK 100,532 |
+-------------------------------------------------------------------+
Definitions and background information:
Publication
Publication shall take place the day after Novo Nordisk receives
sufficient information on the trading. Publication is only required
when the total amount of transactions of a specific board
member/executive and his/her associated persons in any one calendar
year has reached 5,000 euros.
Who are board members, executives and associated persons?
Board members and executives are members of the Board of Directors
and Executive Management, respectively, of Novo Nordisk A/S.
Associated persons are defined as the following persons associated to
a board member/executive: 1) spouse or cohabitant, 2) children under
the age of 18 years, 3) relatives defined as brothers, sisters,
parents, grandparents etc, children, grandchildren etc who have
shared the same household with a board member/executive for at least
one year, and 4) any legal person, including a company, a foundation
or a partnership, which is controlled directly or indirectly by a
board member/executive and/or a person mentioned in 1)-3), or to
which a board member/executive and/or a person mentioned in 1)-3) has
managerial responsibilities or economic interests substantially
equivalent to the legal person.
What is trading/transaction?
Trading is any kind of transaction, including shares purchased or
otherwise acquired, shares sold or otherwise disposed, gifts,
mortgages and grants and exercise of options, but not heritage.
What is financial instrument and ID code?
Financial instrument includes shares listed on the NASDAQ OMX
Copenhagen and London Stock Exchange as well as ADRs listed on New
York Stock Exchange, except for ADRs held in 401(k) retirement plan
by US-based employees. The ID code is the code (ISIN DK006010261) of
the Novo Nordisk share on the NASDAQ OMX Copenhagen, the code (NVOB)
on London Stock Exchange or the code (NVO) on New York Stock
Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place of
transaction is the actual place of transaction, ie NASDAQ OMX
Copenhagen, London Stock Exchange or New York Stock Exchange.
What is volume and value of transaction?
The volume of transaction is the number of shares (of DKK 1 nominal
value) or other financial instruments traded. The transaction value
is the number of shares traded multiplied by the transaction price.
The exchange rate of the Danish Central Bank (Nationalbanken) on the
date of transaction is used for calculating the transaction value in
DKK in case of shares traded on London Stock Exchange and ADRs listed
on New York Stock Exchange.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs over 27,000 employees
in 81 countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen
and London. Its ADRs are listed on the New York Stock Exchange under
the symbol 'NVO'. For more information, visit novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
E-mail: ekh@novonordisk.com E-mail: mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
E-mail: krop@novonordisk.com
In North America: In North America
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
E-mail: secl@novonordisk.com E-mail: hrmm@novonordisk.com
Company Announcement no 7 / 2009
